One-step Nucleic Acid Amplification Assay for Intraoperative Prediction of Advanced Axillary Lymph Node Metastases in Breast Cancer Patients with Sentinel Lymph Node Metastasis

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2016 Feb 20

PMID 26893855

Citations 8

Authors

Michiyo Kubota

Yoshifumi Komoike

Mika Hamada

Wataru Shinzaki

Tatsuya Azumi

Yukihiko Hashimoto

Shigeru Imoto

Yoshifumi Takeyama

Kiyotaka Okuno

Affiliations

Soon will be listed here.

Abstract

The one-step nucleic acid amplification (OSNA) assay is used to semiquantitatively measure the cytokeratin (CK)19 mRNA copy numbers of each sentinel lymph node (SLN) in breast cancer patients. The aim of the present study was to evaluate whether the diagnosis of ≥4 LN metastases is possible using the OSNA assay intraoperatively. Between May, 2010 and December, 2014, a total of 134 patients who underwent axillary lymph node dissection (ALND) of positive SLNs were analyzed. The total tumor load (TTL) was defined as the total CK19 mRNA copies of all positive SLNs. The correlation between TTL and ≥4 LN metastases was evaluated. Of the 134 patients, 31 (23.1%) had ≥4 LN metastases. TTL ≥5.4×10 copies/µl evaluated by receiver operator characteristic curve analysis was examined along with other clinicopathological variables. In the multivariate analysis, only TTL ≥5.4×10 copies/µl was correlated with ≥4 LN metastases (odds ratio = 2.95, 95% confidence interval: 1.17-7.97, P=0.022). Therefore, TTL assessed by the OSNA assay has the potential to be a predictor of ≥4 LN metastases and it may be useful for the selection of patients with positive SLNs in whom ALND may be safely omitted.

Citing Articles

Can one-step nucleic acid amplification assay predict four or more positive axillary lymph node involvement in breast cancer patients: a single-centre retrospective study.

Kenny R, Wong G, Gould L, Odofin O, Bowyer R, Sotheran W Ann R Coll Surg Engl. 2021; 104(3):216-220.

PMID: 34928727 PMC: 10334894. DOI: 10.1308/rcsann.2021.0154.

External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients.

Pinero-Madrona A, Ripoll-Orts F, Sanchez-Mendez J, Chaves-Benito A, Gomez-de la Barcena M, Calatrava-Fons A Breast Cancer Res Treat. 2020; 181(2):339-345.

PMID: 32253684 PMC: 7188708. DOI: 10.1007/s10549-020-05623-4.

Nomogram to predict non-sentinel lymph node status using total tumor load determined by one-step nucleic acid amplification: first report from Thailand.

Sa-Nguanraksa D, O-Charoenrat E, Kulprom A, Samarnthai N, Lohsiriwat V, Nimpoonsri K Breast Cancer. 2019; 26(4):471-477.

PMID: 30617675 DOI: 10.1007/s12282-019-00945-8.

One-step nucleic acid amplification: the possible value in assessing sentinel lymph node metastasis during mastectomy.

Hunter-Smith A, Rayter Z Breast Cancer (Dove Med Press). 2018; 10:13-21.

PMID: 29416374 PMC: 5790072. DOI: 10.2147/BCTT.S113737.

Intraoperative prediction of the two axillary lymph node macrometastases threshold in patients with breast cancer using a one-step nucleic acid cytokeratin-19 amplification assay.

Fung V, Kohlhardt S, Vergani P, Zardin G, Williams N Mol Clin Oncol. 2017; 7(5):755-762.

PMID: 29142748 PMC: 5666659. DOI: 10.3892/mco.2017.1404.

References

Espinosa-Bravo M, Sansano I, Perez-Hoyos S, Ramos M, Sancho M, Xercavins J . Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. Eur J Surg Oncol. 2013; 39(7):766-73. DOI: 10.1016/j.ejso.2013.03.011. View

Osako T, Iwase T, Kimura K, Horii R, Akiyama F . Sentinel node tumour burden quantified based on cytokeratin 19 mRNA copy number predicts non-sentinel node metastases in breast cancer: molecular whole-node analysis of all removed nodes. Eur J Cancer. 2012; 49(6):1187-95. DOI: 10.1016/j.ejca.2012.11.022. View

Chu K, Turner R, Hansen N, Brennan M, Bilchik A, Giuliano A . Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?. Ann Surg. 1999; 229(4):536-41. PMC: 1191740. DOI: 10.1097/00000658-199904000-00013. View

Rivers A, Griffith K, Hunt K, Degnim A, Sabel M, Diehl K . Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol. 2005; 13(1):36-44. DOI: 10.1245/ASO.2006.03.080. View

Galimberti V, Cole B, Zurrida S, Viale G, Luini A, Veronesi P . Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14(4):297-305. PMC: 3935346. DOI: 10.1016/S1470-2045(13)70035-4. View

Reynolds C, Mick R, Donohue J, Grant C, Farley D, Callans L . Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?. J Clin Oncol. 1999; 17(6):1720-6. DOI: 10.1200/JCO.1999.17.6.1720. View

Ohi Y, Umekita Y, Rai Y, Yotsumoto D, Matsukata A, Baba S . Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer. Br J Cancer. 2012; 107(8):1239-43. PMC: 3494436. DOI: 10.1038/bjc.2012.387. View

Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F . One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007; 13(16):4807-16. DOI: 10.1158/1078-0432.CCR-06-2512. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

10.

Bilimoria K, Bentrem D, Hansen N, Bethke K, Rademaker A, Ko C . Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009; 27(18):2946-53. DOI: 10.1200/JCO.2008.19.5750. View

11.

van la Parra R, Peer P, Ernst M, Bosscha K . Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol. 2011; 37(4):290-9. DOI: 10.1016/j.ejso.2011.01.006. View

12.

Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P, Blumencranz P . Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305(6):569-75. PMC: 5389857. DOI: 10.1001/jama.2011.90. View

13.

Recht A, Edge S, Solin L, Robinson D, Estabrook A, Fine R . Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(5):1539-69. DOI: 10.1200/JCO.2001.19.5.1539. View

14.

Overgaard M, Nielsen H, Overgaard J . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007; 82(3):247-53. DOI: 10.1016/j.radonc.2007.02.001. View

15.

Katz A, Smith B, Golshan M, Niemierko A, Kobayashi W, Raad R . Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol. 2008; 26(13):2093-8. DOI: 10.1200/JCO.2007.11.9479. View

16.

Sagara Y, Ohi Y, Matsukata A, Yotsumoto D, Baba S, Tamada S . Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer. Breast Cancer. 2011; 20(2):181-6. DOI: 10.1007/s12282-011-0324-z. View

17.

Donker M, van Tienhoven G, Straver M, Meijnen P, van de Velde C, Mansel R . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(12):1303-10. PMC: 4291166. DOI: 10.1016/S1470-2045(14)70460-7. View

18.

Yi M, Giordano S, Meric-Bernstam F, Mittendorf E, Kuerer H, Hwang R . Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010; 17 Suppl 3:343-51. PMC: 4324560. DOI: 10.1245/s10434-010-1253-3. View

19.

Lyman G, Giuliano A, Somerfield M, Benson 3rd A, Bodurka D, Burstein H . American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23(30):7703-20. DOI: 10.1200/JCO.2005.08.001. View

20.

Meretoja T, Audisio R, Heikkila P, Bori R, Sejben I, Regitnig P . International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat. 2013; 138(3):817-27. DOI: 10.1007/s10549-013-2468-3. View